Literature DB >> 33866424

Renal Implications of Left Renal Vein Ligation for Portal Flow Augmentation in Liver Transplantation.

Sadhana Shankar1, Ashwin Rammohan2, Balaji Balasubramanian1, Kumar Palaniappan1, Rajesh Rajalingam1, Mohamed Rela1.   

Abstract

BACKGROUND: Spontaneous lienorenal shunts (SLS) siphon blood away from the portal circulation and may compromise portal inflow in liver transplantation (LT). Performing a left renal vein ligation (LRVL) is a relatively easy and efficacious method of overcoming this portal 'steal'. However, given the delicate state of renal function in these patients, its short and long term effects remain undefined. The aim of this study was to evaluate the efficacy of LRVL in augmenting portal flow and safety with regards to renal function.
METHODS: A prospectively collected database of 1638 consecutive LT recipients between January 2010 and August 2020 was reviewed. Twenty-eight patients who underwent LRVL were identified. There were six paediatric recipients, who were analysed separately. Data with regards to imaging, renal function, intraoperative portal hemodynamics, and renal morbidity were analysed.
RESULTS: Of the 22 adults, 21 underwent live donor LT. 22.5% had a pre-transplant history of acute kidney injury (AKI). Pre-operative CT demonstrated portal vein thrombosis and SLS in 63.6% and 92.9% of patients respectively. LRVL resulted in a significant augmentation of portal hemodynamics in both the adult and paediatric recipients. Postoperatively, 14.3% and 35.7% of patients developed chylous drain output and AKI respectively. Of 13 patients who underwent CT at various timeframes, 5 patients had a partial re-canalisation of LRV at 6 months.
CONCLUSION: From renal and portal standpoints, LRVL is a safe and effective technique of augmenting portal inflow. Further large-scale multicentre studies and consensus will help define an objective algorithmic approach to LT recipients with SLS.

Entities:  

Year:  2021        PMID: 33866424     DOI: 10.1007/s00268-021-06112-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  7 in total

Review 1.  Portosystemic collaterals in living donor liver transplantation: What is all the fuss about?

Authors:  Mettu Srinivas Reddy; Mohamed Rela
Journal:  Liver Transpl       Date:  2017-04       Impact factor: 5.799

2.  Surgical Management of Large Spontaneous Portosystemic Splenorenal Shunts During Liver Transplantation: Splenectomy or Left Renal Vein Ligation?

Authors:  N Golse; K Mohkam; A Rode; S Mezoughi; H Demian; C Ducerf; J-Y Mabrut
Journal:  Transplant Proc       Date:  2015 Jul-Aug       Impact factor: 1.066

3.  Ligation of left renal vein for large spontaneous splenorenal shunt to prevent portal flow steal in adult living donor liver transplantation.

Authors:  Sung-Gyu Lee; Deok-Bog Moon; Chul-Soo Ahn; Ki-Hun Kim; Shin Hwang; Kwang-Min Park; Tae-Yong Ha; Gi-Young Ko; Kyu-Bo Sung; Gi-Won Song; Dong-Hwan Jung; Ki-Myung Moon; Bum-Soo Kim; Yong-Pil Cho
Journal:  Transpl Int       Date:  2007-01       Impact factor: 3.782

Review 4.  Perioperative management of spontaneous splenorenal shunts in orthotopic liver transplant patients.

Authors:  Nadia Awad; Mindy M Horrow; Afshin Parsikia; Paul Brady; Radi Zaki; Michael D C Fishman; Jorge Ortiz
Journal:  Exp Clin Transplant       Date:  2012-08-11       Impact factor: 0.945

5.  Left renal vein division during open surgery of abdominal aortic disease: a propensity score-matched case-control study.

Authors:  L Wang; S J Xin; Z Song; J Zhang
Journal:  Eur J Vasc Endovasc Surg       Date:  2013-06-03       Impact factor: 7.069

6.  Long-term safety of left renal vein division and ligation to expedite complex abdominal aortic surgery.

Authors:  Russell H Samson; Michael R Lepore; David P Showalter; Deepak G Nair; Julien B Lanoue
Journal:  J Vasc Surg       Date:  2009-09       Impact factor: 4.268

Review 7.  Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).

Authors:  John A Kellum; Norbert Lameire
Journal:  Crit Care       Date:  2013-02-04       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.